ANALYSIS, NOT A POSITION. Quality Criteria FAIL on all three INFLECTION limbs, every input present: gross margin 23.8%, operating margin -3,813% and deteriorating, revenue DECLINING (FY2024 $37.045m to FY2025 $31.479m; Q1'26 $0.565m against Q1'25 $13.375m, -96%). Valuation Criteria FAIL by the widest margin in the batch: the $1,992m enterprise value requires a 124.2% revenue CAGR for five years against 15.1% demonstrated - a margin of -109.1pp. THE PRICE CANNOT BE JUSTIFIED ANYWHERE IN THE PLAUSIBLE PARAMETER RANGE, holding TTM revenue and the growth-matched terminal margin fixed: the margin is negative at every exit multiple tested, and the flip point is 631.1x EV/EBIT, which lies OUTSIDE reverse_dcf.solve()'s 0.1x-200x bounds entirely and had to be derived by hand. Two data corrections were required first: the share count (365,481,156 Class A+B from the 10-Q cover, against 236,754,948 from a 2022 cover page - a 54% error) and TTM revenue ($18.669m against $30.236m). 12-month target $5.15-$22.17, a 4.3x band whose entire width comes from an 8.1x disagreement about FY2026 revenue (Street $53.5m vs house $6.6m), not from the multiple. The ENTRA1 asymmetry stands: a binding TVA PPA crystallises a $1,246.8m fee, 123% of total cash, forcing a 12-25% equity issue - the good news and the funding hole arrive in the same 8-K. No insolvency case is argued: 5.9 years of runway, zero borrowings.
How to read this
This is an analysis, not a position. The memo scores every Criteria and blocks on none of them. Whether an analysis justifies a position is a question about a particular book, and two books answer it differently — so this page carries no Long, Short, Watchlist or Avoid verdict. The previous verdict has been retired.
Every Criteria returns PASS / FAIL / INDETERMINATE, and carries a type. BINDING criteria are admission tests for a long-only absolute-return strategy. MEASURED criteria are always scored and stored, and never block — they inform timing, sizing or a future strategy. A missing input is INDETERMINATE, never FAIL.
Two valuation outputs, over two horizons. The implied-path test (reverse DCF) asks what today's price requires over five years and whether the business has demonstrated it; the 12-month target asks what the name is likely to trade at, on near-term consensus and the name's own multiple history. Neither replaces the other. Sensitivity is run over the exit multiple, never over scenario probabilities.
Momentum is entry timing only. It governs when to enter a position the thesis already justifies, never whether to own one.
Key findings
- The mechanism is specific, named and EVIDENCED rather than a valuation observation: NuScale has contracted away the commercialisation of its own product to 2045. ENTRA1 — not NuScale — is the counterparty to every customer document, and under the FILED Partnership Milestones Agreement NuScale PAYS ENTRA1 in cash as commercial progress occurs.
- Roughly $46.98m per 77 MWe module in total (15% on a non-binding letter, 35% on ENTRA1's binding PPA, 50% on the OEM agreement), escalating at the greater of 5% or CPI every 1 January to ~$63m by a 2031 delivery, guaranteed by the listed parent as primary obligor and payable within 60 days of invoice with no set-off.
- $507.393m was expensed and fully paid on a NON-BINDING MOU alone (EDGAR us-gaap:BusinessDevelopment, FY2025).
- Management's own guidance for what a TVA PPA is worth in revenue is 'about $8 million' on the RoPower analogue, against $207m of Milestone 2 cash per twelve-module plant — a ratio of roughly 26:1, cash OUT to revenue IN, at the moment the good news arrives.
- Deterioration is observed rather than forecast: Q1-2026 revenue fell 95.8% y/y to $0.565m; deferred revenue is $1.409m; there are ZERO binding reactor orders; first commercial module delivery is 2031 at the earliest; operating cash flow has been negative in every year of the company's existence.
- Piotroski F-score 0/9, accruals +0.106, gross profitability 0.008. BUT $1,013.9m of cash and investments, zero borrowings and 5.9 years of runway: this is a business with no revenue and no solvency problem.
- Delta-E is large on revenue and on the price target and zero-to-negative on EPS. FY2026E revenue: Street $53.5m vs house $6.6m (-87.7%). FY2027E revenue: Street $169.3m vs house $18.0m (-89.4%). FY2026E EPS in line; FY2027E EPS the house is BETTER (-$0.53 vs -$0.734). 12m price target: Street $14.57 average vs house $6.75 (-54%). Implied eventual GW delivery: Street 18.5 GW vs house 6.4 GW (-65%).
- The variant is real but SPECIFIC: it concerns the revenue trajectory, the ENTRA1 cash-obligation structure and the implied module count — NOT the P&L loss, where the Street is already more bearish. The house target of $6.75 sits between Goldman's $6.00 and Citi's $7.50 — at the bearish edge of the Street, not beyond it.
- Today's $2,021.6m EV implies 8.8 GW = 1.47x the entire announced TVA programme must eventually be delivered, against 0.0 GW of binding orders. Fair value under the differentiated forecast is $6.75 (-18.6%), with a bear at $4.50 and a net-cash floor of $2.76.
- The probability-weighted target of $8.41 sits against a spot of $8.29 — the gap the analysis identifies has largely already been paid for.
- The v1.4.0 re-run made the thesis materially better AND the right tail fatter, and the two corrections nearly cancel: gross E[R] moved from -1.5% to +2.3% and net from -4.0% to -0.2%, while the gate still fails by 4.9pp.
Sections
Disclosed limitations
- NO DCF IS BUILT, and that is a deliberate methodological refusal rather than an omission. Every line of a five- or ten-year DCF on this company would be an assumption, and the output would move by a factor of five on inputs that are not disclosed anywhere (gross profit per module, module count, delivery schedule). That is not a valuation; it is a spreadsheet-shaped opinion with false precision. Three tools are used instead, in descending order of reliability, led by liquidity-runway analysis — the only fully sourced valuation-relevant work available.
- Product-level revenue and geographic detail are not disclosed by the company; nothing is presented as fact that is not sourced, and every unsourced figure is explicitly labelled ESTIMATE or FLAGGED.
- Alpha Vantage's EARNINGS_CALL_TRANSCRIPT endpoint was quota-exhausted before the task began, so transcripts were taken from the stockanalysis.com archive and cached. The substitution is disclosed, and a cross-source discrepancy that was caught is documented rather than smoothed over.
- The whole thesis turns on one item that the filings do not settle: whether the remaining ENTRA1 milestone obligations are payable in CASH or in stock, and on what schedule. It is the highest-value item to verify at the Q2-2026 print on 2026-08-05.
- The second open question is the TVA definitive PPA decision, guided by year-end 2026.